Pamela Arterbridge noticed something was wrong back in 2013 when she woke up one morning, and her legs and feet were tingling.
Two years later, Lorraine Lee knew she had a problem when her right leg became extremely fatigued after every workout.
Neither realized their eventual diagnosis would be multiple sclerosis (MS).
Arterbridge, a 46-year-old, self-employed hairstylist from Columbus, Ohio, and Lee, 55, a registered nurse in suburban Austin, Texas, have different forms of MS. But both say Ocrevus (ocrelizumab) — an intravenous infusion therapy the U.S. Food and Drug Administration approved last month — has dramatically improved their lives.
No more injections
“Prior to the numbness and tingling, I was just really tired and drained all the time. My family doctor did blood work, and said I had low vitamin D,” Arterbridge told MS News Today in a phone interview. “A year later, one day, I woke up and felt sensations going up and down my legs. I went back to my doctor and had an MRI. When the results came back, she sent me to see a neurologist. I was devastated [at the MS diagnosis]. I was concerned that my career would be over.”
Arterbridge learned she had a lesion on her spine and three on her brain. Eventually, she was referred to Dr. Michael Racke, a neurologist at Ohio State University’s Wexner Medical Center and a pioneer in B-cell therapies for MS.
Like 85 percent of patients diagnosed with MS, Arterbridge was told she had the relapsing-remitting form, known as RRMS.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?